• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:曹彬,毕建杰.心脉隆注射液联合西药应用于冠心病心力衰竭患者治疗的临床疗效及血浆NT-proBNP的影响[J].药学研究,2021,40(1):60-61[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2534次   下载 2592次 本文二维码信息
码上扫一扫!
心脉隆注射液联合西药应用于冠心病心力衰竭患者治疗的临床疗效及血浆NT-proBNP的影响
曹彬1,毕建杰2
字体:加大+|默认|缩小-
(1.博兴县人民医院,山东 博兴 256500;2.山东明仁福瑞达制药股份有限公司,山东 济南 250104)
摘要:
目的 对于冠心病心力衰竭患者,探究实施西药+心脉隆注射液共同治疗对血浆NT-proBNP以及临床疗效的影响。方法 本次研究随机挑选1年内(2019年02月至2020年02月)到院治疗的冠心病心力衰竭患者70例进行研究,根据实施治疗方式不同将其分为35例基础组和35例实验组。将西药用于治疗35例基础组患者,将西药+心脉隆注射液用于治疗35例实验组患者。分别对2组患者治疗前后血浆NT-proBNP 水平变化情况以及临床疗效进行比对。 结果 治疗后与实验组相对比,参照组患者血浆NT-proBNP水平显著偏高,(P<0.05);治疗后与实验组相对比,参照组患者总有效率显著偏低,(P<0.05)。结论 将血浆NT-proBNP 水平联合用于治疗临床收治的冠心病心力衰竭患者,可显著提升整体临床疗效,同时改善患者血浆NT-proBNP 水平。
关键词:  冠心病  心力衰竭  西药  心脉隆注射液
DOI:10.13506/j.cnki.jpr.2021.01.012
基金项目:
Clinical efficacy of Xinmailong Injection combined with western medicine in the treatment of patients with coronary heart disease and heart failure and the effect of plasma NT-proBNP
CAO Bin1,BI Jianjie2
(Boxing People’s Hospital,Boxing 256500,China)
Abstract:
Objective To explore the effect of western medicine plus Xinmailong Injection on plasma NT-proBNP and clinical efficacy in patients with coronary heart disease and heart failure.Methods This study randomly selected 70 patients with coronary heart disease and heart failure who came to hospital for treatment within one year (February 2019 to February 2020) and divided them into 35 basic groups and 35 experimental groups according to different treatment methods. Western medicine was used to treat 35 patients in the basic group and western medicine+Xinmailong injection was used to treat 35 patients in the experimental group. The changes of plasma NT-proBNP level and clinical efficacy of the two groups were compared before and after treatment respectively.Results Compared with the experimental group, the plasma NT-proBNP level in the reference group was significantly higher (p < 0.05). Compared with the experimental group after treatment, the total effective rate in the reference group was significantly lower (P<0.05).Conclusion The combination of plasma NT-proBNP level and clinical treatment for patients with coronary heart disease and heart failure can significantly improve the overall clinical efficacy and improve the plasma NT-proBNP level of patients.
Key words:  Coronary Heart Disease  Heart failure  Western medicine  Xinmailong injection
今日访问量:2490    总访问量:55338932
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司